

Approved



Burundi
Country Operational Plan
FY 2018



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
USAID		9,819,763	3,500,000	13,319,763	160,237	13,480,000
DOD		1,520,000		1,520,000	0	1,520,000
Total	0	11,339,763	3,500,000	14,839,763	160,237	15,000,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency			Total
	DOD	State/SGAC	USAID	
CIRC	0		0	0
HBHC	0		309,801	309,801
HKID	0		1,220,000	1,220,000
HLAB	180,000		1,832,543	2,012,543
HMBL	0		0	0
HMIN	0		0	0
HTXD	0		715,195	715,195
HTXS	280,500		2,387,524	2,668,024
HVAB	0		0	0
HVCT	170,500		1,694,163	1,864,663
HVMS	120,000		867,873	987,873
HVOP	270,000		1,391,083	1,661,083
HVSI	150,000		200,000	350,000
HVTB	16,500		189,453	205,953
IDUP	0		0	0
MTCT	180,000		553,963	733,963

Approved



OHSS	70,000	0	1,432,421	1,502,421
PDCS	44,000		138,762	182,762
PDTX	38,500		386,982	425,482
	1,520,000	0	13,319,763	14,839,763



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount
HBHC	309,801
HKID	1,220,000
HVTB	205,953
PDCS	182,762
Total Technical Area Planned Funding:	1,918,516

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount
HLAB	2,012,543
HVSI	350,000
OHSS	1,502,421
Total Technical Area Planned Funding:	3,864,964

Technical Area: Prevention

Budget Code	Budget Code Planned Amount
CIRC	0
HMBL	0
HMIN	0
HVAB	0
HVCT	1,864,663
HVOP	1,661,083
IDUP	0
MTCT	733,963
Total Technical Area Planned Funding:	4,259,709

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount
HTXD	715,195
HTXS	2,668,024
PDTX	425,482
Total Technical Area Planned Funding:	3,808,701



Technical Area Summary Indicators and Targets

Indicator Number	Label	2019
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	95 %
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	183,295
	Number of new ANC and L&D clients	192,640
	By Age (Denominator): 10-14	2
	By Age (Denominator): <15-19	23,160
	By Age (Denominator): 20-24	57,146
	By Age (Denominator): 50+	1
	By Number of known positives: 15-19	32
	By Number of known positives: 20-24	255
	By Number of known positives: 50+	4
	By Number of new positives: 15-19	139
	By Number of new positives: 20-24	399
	By Number of new negative: 10-14	2
	By Number of new negative: 15-19	20,994
	By Number of new negative: 20-24	53,337
	By Number of new negative: 50+	1
	By Age (Numerator): 10-14	2
	By Age (Numerator): 15-19	21,136
	By Age (Numerator): 20-24	53,867



	By Age (Numerator): 50+	4
	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	25,640
	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	32,150
	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	33,490
	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	21,051
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Known at Entry Positive	251
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Negative	24,303
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 25-29, Female, Newly Identified Positive	148
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Known at Entry Positive	305
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Negative	29,709
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 30-34, Female, Newly Identified Positive	211
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Known at Entry Positive	337
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female, Newly Identified Negative	32,534
	PMTCT_STAT_N_DSD_Age_Sex_ KnownNewResult 35-39, Female,	224



	Newly Identified Positive	
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	222
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	19,735
	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	131
	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	24,670
	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	30,196
	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	33,351
	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	20,062
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,462
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	183,295
	New on ART	1,096
	Already on ART at beginning of current pregnancy	1,366



PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	19,000
	Age/sex: 10-14 Male	190
	Age/sex: 15-19 Male	760
	Age/sex: 20-24 Male	1,900
	Age/sex: 50+ Male	570
	Age/sex: 10-14 Female	190
	Age/sex: 15-19 Female	950
	Age/sex: 20-24 Female	1,520
	Age/sex: 50+ Female	190
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Female	1,140
	PP_PREV_N_DSD_Age_Sex_v2 25-29, Male	2,090
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Female	1,140
	PP_PREV_N_DSD_Age_Sex_v2 30-34, Male	2,090
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Female	1,140
	PP_PREV_N_DSD_Age_Sex_v2 35-39, Male	2,090
	PP_PREV_N_DSD_Age_Sex_v2 40-49, Female	1,140
	PP_PREV_N_DSD_Age_Sex_v2	1,900



	40-49, Male	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,797
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,181
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	788
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the	249



	minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	167
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14,412
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	144
	Total number of registered new and relapsed TB cases, during the reporting period.	144
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered	85



	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	51
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	85
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	51
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and	2,375



	relapsed TB cases with documented HIV status, during the reporting period.	
	Total number of registered new and relapsed TB cases, during the reporting period.	2,375
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	51
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	69
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	872
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,383
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	61
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,383
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with	58



	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	873
HTS_SELF_DSD	HTS_SELF_N_DSD	10,624
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Directly-Assisted	108
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Female, Unassisted	108
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Directly-Assisted	108
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 10-14, Male, Unassisted	108
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Directly-Assisted	531
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Female, Unassisted	531
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Directly-Assisted	531
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 15-19, Male, Unassisted	531
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female, Directly-Assisted	634
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Female,	215



	Unassisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Directly-Assisted	634
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 20-24, Male, Unassisted	215
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Directly-Assisted	634
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Female, Unassisted	215
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Directly-Assisted	634
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 25-29, Male, Unassisted	215
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Directly-Assisted	634
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Female, Unassisted	215
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Directly-Assisted	634
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 30-34, Male, Unassisted	215
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Directly-Assisted	634
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Female, Unassisted	215
	HTS_SELF_N_DSD_Age_Sex_HI	634



	VSelfTest 35-39, Male, Directly-Assisted	
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 35-39, Male, Unassisted	215
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Directly-Assisted	423
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Female, Unassisted	215
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Directly-Assisted	423
	HTS_SELF_N_DSD_Age_Sex_HI VSelfTest 40-49, Male, Unassisted	215
	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	7,196
	HTS_SELF_N_DSD_HIVSelfTest Unassisted	3,428
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Other	677
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Self	678
	HTS_SELF_N_DSD_HIVSelfTestU ser Unassisted - Sex Partner	2,073
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Directly-Assisted	3,490
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest FSW, Unassisted	1,660
	HTS_SELF_N_DSD_KeyPop_HIV SelfTest MSM, Directly-Assisted	3,528
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	462,302



	months	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	224
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	224
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	450
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	5
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	234
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	5
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	968
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	28
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	517
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	37
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	475
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	29
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	491
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	76
	Service Delivery Point (Facility) Inpatient: <1, Negative	57
	Service Delivery Point (Facility) Inpatient: <1, Positive	2
	Service Delivery Point (Facility)	599



	Inpatient: 1-9, Negative	
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	40
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,784
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	47
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	658
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	24
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	3,803
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	412
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,748
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	24
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	109
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	79
	Service Delivery Point (Facility) Other PITC: 10-14, Female,	706



	Negative	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	4
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	25
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	583
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	12
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	32
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,521
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	49
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	168
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	81
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	74
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	4
	Service Delivery Point (Facility)Other PITC: <1, Negative	27
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	125
	Service Delivery Point (Community) Other: 15-19, Female, Negative	734



	Service Delivery Point (Community) Other: 15-19, Female, Positive	1
	Service Delivery Point (Community) Other: 15-19, Male, Positive	1
	Service Delivery Point (Community) Other: 20-24, Female, Negative	1,652
	Service Delivery Point (Community) Other: 20-24, Female, Positive	4
	Service Delivery Point (Community) Other: 20-24, Male, Negative	122
	Service Delivery Point (Community) Other: 50+, Female, Negative	245
	Service Delivery Point (Facility) Pediatric : <5 Negative	1,106
	Service Delivery Point (Facility) Pediatric : <5 Positive	14
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	29
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	4
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	25
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	5
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	53
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	8
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	58
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	9
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	108



	Service Delivery Point (Facility) TB: 20-24, Female, Positive	16
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	109
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	15
	Service Delivery Point (Facility) TB: 50+, Female, Negative	157
	Service Delivery Point (Facility) TB: 50+, Female, Positive	14
	Service Delivery Point (Facility) TB: 50+, Male, Negative	271
	Service Delivery Point (Facility) TB: 50+, Male, Positive	34
	Service Delivery Point (Facility) TB: <1, Negative	7
	Service Delivery Point (Facility) TB: <1, Positive	1
	Service Delivery Point (Facility) TB: 1-9, Negative	41
	Service Delivery Point (Facility) TB: 1-9, Positive	8
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	340
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	10
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	286
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	3
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3,255
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	48



Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,986
Service Delivery Point (Facility) Index: 15-19, Male, Positive	24
Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,029
Service Delivery Point (Facility) Index: 20-24, Female, Positive	234
Service Delivery Point (Facility) Index: 20-24, Male, Negative	2,087
Service Delivery Point (Facility) Index: 20-24, Male, Positive	26
Service Delivery Point (Facility) Index: 50+, Female, Negative	430
Service Delivery Point (Facility) Index: 50+, Female, Positive	29
Service Delivery Point (Facility) Index: 50+, Male, Negative	711
Service Delivery Point (Facility) Index: 50+, Male, Positive	152
Service Delivery Point (Facility) Index: <1, Negative	252
Service Delivery Point (Facility) Index: <1, Positive	4
Service Delivery Point (Facility) Index: 1-9, Negative	1,430
Service Delivery Point (Facility) Index: 1-9, Positive	26
By Key Population: FSW, Negative	12,866
By Key Population: FSW, Positive	982
By Key Population: MSM, Negative	5,243
By Key Population: MSM, Positive	119
By Key Population: People in prisons and other enclosed	523



	settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	28
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	4
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	1
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	8
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	3
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	1
	Service Delivery Point (Facility) ANC: 15-19, Negative	20,485
	Service Delivery Point (Facility) ANC: 15-19, Positive	90
	Service Delivery Point (Facility) ANC: 20-24, Negative	54,236
	Service Delivery Point (Facility) ANC: 20-24, Positive	367
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,755
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	15
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2,007



	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	36
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	20,298
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	377
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	8,973
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	128
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	31,679
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	867
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	19,885
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	212
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,997
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	274
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	3,933
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	251
	Service Delivery Point (Facility) VCT: <1, Negative	1,027
	Service Delivery Point (Facility) VCT: <1, Positive	20
	Service Delivery Point (Facility) VCT: 1-9, Negative	8,197
	Service Delivery Point (Facility) VCT: 1-9, Positive	81



HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,265
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	120
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,236
HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	150
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,889
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	169
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,476
HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	189
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,747
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	172
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,696
HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	200
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	1,136
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	106
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,071
HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	136
HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	523



	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Female, Positive	33
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Negative	359
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 25-29, Male, Positive	23
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Negative	640
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Female, Positive	39
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Negative	409
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 30-34, Male, Positive	25
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Negative	661
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Female, Positive	43
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Negative	478
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 35-39, Male, Positive	26
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Negative	443
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Female, Positive	31
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Negative	317
	HTS_TST_N_DSD_Inpat_Age_Sex _Result 40-49, Male, Positive	16
	HTS_TST_N_DSD_MbMod_Age_ Sex_Result 25-29, Female, Negative	475
	HTS_TST_N_DSD_MbMod_Age_	91



	Sex_Result 25-29, Female, Positive	
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	533
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	43
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	3,456
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	192
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,117
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	11
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	878
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	124
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	504
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	470
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	27
	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	24
	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	248



	HTS_TST_N_DSD_MN_Age_Sex_ Result <5, Unknown Sex, Positive	6
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 25-29, Female, Negative	2
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Female, Negative	10
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 30-34, Female, Positive	2
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Female, Negative	2
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 35-39, Female, Positive	1
	HTS_TST_N_DSD_NdxMod_Age_ Sex_Result 40-49, Female, Negative	2
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Female, Negative	652
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Female, Positive	17
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 25-29, Male, Negative	128
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Negative	898
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 30-34, Female, Positive	25
	HTS_TST_N_DSD_OtPITC_Age_	211



	Sex_Result 30-34, Male, Negative	
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Negative	887
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Female, Positive	25
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Negative	214
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 35-39, Male, Positive	2
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Negative	588
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Female, Positive	17
	HTS_TST_N_DSD_OtPITC_Age_ Sex_Result 40-49, Male, Negative	156
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Female, Negative	306
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 25-29, Male, Negative	61
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Female, Negative	2,019
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Female, Positive	2
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 30-34, Male, Negative	61
	HTS_TST_N_DSD_OtrMod_Age_ Sex_Result 35-39, Female, Negative	489



HTS_TST_N_DSD_OtrMod_Age_Sex_Result 35-39, Female, Positive	2
HTS_TST_N_DSD_OtrMod_Age_Sex_Result 40-49, Female, Negative	428
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	23,587
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	165
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	30,023
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	220
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	30,762
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	263
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	21,542
HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	151
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	102
HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	20
HTS_TST_N_DSD_TBC_Age_Sex	120



	_Result 25-29, Male, Negative	
	HTS_TST_N_DSD_TBC_Age_Sex _Result 25-29, Male, Positive	18
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Female, Negative	159
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Female, Positive	22
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Negative	157
	HTS_TST_N_DSD_TBC_Age_Sex _Result 30-34, Male, Positive	19
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Negative	146
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Female, Positive	22
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Negative	158
	HTS_TST_N_DSD_TBC_Age_Sex _Result 35-39, Male, Positive	22
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Negative	112
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Female, Positive	21
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Negative	123
	HTS_TST_N_DSD_TBC_Age_Sex _Result 40-49, Male, Positive	23
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Negative	11,769
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Female, Positive	480
	HTS_TST_N_DSD_VCT_Age_Sex _Result 25-29, Male, Negative	10,641
	HTS_TST_N_DSD_VCT_Age_Sex	254



	_Result 25-29, Male, Positive	
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Negative	17,073
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Female, Positive	696
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Negative	14,090
	HTS_TST_N_DSD_VCT_Age_Sex _Result 30-34, Male, Positive	316
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Negative	16,096
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Female, Positive	686
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Negative	13,942
	HTS_TST_N_DSD_VCT_Age_Sex _Result 35-39, Male, Positive	365
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Negative	10,146
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Female, Positive	441
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Negative	9,883
	HTS_TST_N_DSD_VCT_Age_Sex _Result 40-49, Male, Positive	255
GEND_GBV_DSD	Number of people receiving post-GBV care	1,148
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	14
	By type of service: Sexual Violence (Post-Rape Care)	1,134
	By PEP service provision (related to sexual violence services)	870



	provided)	
	<10, Female, Sexual Violence (Post-Rape Care)	167
	<10, Male, Physical and/or Emotional Violence	2
	<10, Male, Sexual Violence (Post-Rape Care)	9
	10-14, Female, Sexual Violence (Post-Rape Care)	143
	10-14, Male, Physical and/or Emotional Violence	1
	10-14, Male, Sexual Violence (Post-Rape Care)	15
	15-19, Female, Sexual Violence (Post-Rape Care)	303
	15-19, Male, Physical and/or Emotional Violence	1
	15-19, Male, Sexual Violence (Post-Rape Care)	16
	20-24, Female, Sexual Violence (Post-Rape Care)	199
	20-24, Male, Physical and/or Emotional Violence	1
	20-24, Male, Sexual Violence (Post-Rape Care)	10
	50+, Female, Physical and/or Emotional Violence	9
	50+, Female, Sexual Violence (Post-Rape Care)	160
	50+, Male, Sexual Violence (Post-Rape Care)	2
	GEND_GBV_N_DSD_Age_Sex_Vi olenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	38



	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	5
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	48
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	14
	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	5
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,037
	Age/Sex: 10-14 Female	5,950
	Age/Sex: 15-17 Female	3,201
	By: Age/sex: 18-24 Female	843
	Sum of Age/Sex disaggregates	9,151
	Program Completion: Active	8,537
OVC_HIVSTAT_DSD	OVC_HIVSTAT_DSD Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	87 %
	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	8,700
	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,037



TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	21
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented	176



	HIV-positive status who are on ART during TB treatment during the reporting period	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	88
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	80
	TB_PREV_TA TB_PREV_TA	85 %
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive	4,184



	Therapy (IPT) during the reporting period	
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,922
	By Age/Sex (Denominator): <15, Female	147
	By Age/Sex (Denominator): <15, Male	113
	By Age/Sex (Denominator): 15+, Female	3,028
	By Age/Sex (Denominator): 15+, Male	1,634
	By Age/Sex (Numerator): <15, Female	125
	By Age/Sex (Numerator): <15, Male	96
	By Age/Sex (Numerator): 15+, Female	2,570
	By Age/Sex (Numerator): 15+, Male	1,393
	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	3,445
	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,477
	TB_PREV_N_TA_TherapyType_N	2,929



	ewExArt_HIV IPT, Life-long ART, Already, Positive	
	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,255
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	2,080
	Denominator: By Aggregated Age/Sex:15+, Female	1,352
	Denominator: By Aggregated Age/Sex:15+, Male	728
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	612
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	15
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	95
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	502
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	516
	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	80



	TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	16
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	0 %
	Number of ART patients who were screened for TB at least once during the reporting period	44,307
	Denominator: By Aggregated Age/Sex: <15, Female	1,329
	Denominator: By Aggregated Age/Sex: <15, Male	1,015
	Denominator: By Aggregated Age/Sex: 15+, Female	27,261
	Denominator: By Aggregated Age/Sex: 15+, Male	14,702
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	43,695
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	4,416
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	13,197
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	26,082
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	30,499
	TX_TB_D_TA_TBScreen_NewExis	4,351



	tingART_HIV Life-long ART, New, TB Screen - Negative, Positive	
	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	8,845
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,468
	By infants who received a virologic test within 2 months of birth	1,977
	By infants who received their first virologic HIV test between 2 and 12 months of age	491
	Sum of Infant Age disaggregates	2,468
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,079
	Age/Sex: 15-19 Male	20
	Age/Sex: 15-19 Female	20
	Age/Sex: <1-9	29
	Age/Sex: 10-14 Male	10
	Age/Sex: 10-14 Female	9
	Age/Sex: 20-24 Male	20
	Age/Sex: 50+ Male	406
	Age/Sex: 20-24 Female	61
	Age/Sex: 50+ Female	284
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Female, Positive	122
	TX_CURR_N_DSD_Age_Sex_HIV Status 25-29, Male, Positive	20



	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Female, Positive	102
	TX_CURR_N_DSD_Age_Sex_HIV Status 30-34, Male, Positive	102
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Female, Positive	122
	TX_CURR_N_DSD_Age_Sex_HIV Status 35-39, Male, Positive	203
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Female, Positive	244
	TX_CURR_N_DSD_Age_Sex_HIV Status 40-49, Male, Positive	305
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	49,230
	Age/Sex: 15-19 Male	742
	Age/Sex: 15-19 Female	927
	Sum of Age/Sex disaggregations	1,669
	Age/Sex: <1	65
	Age/Sex: 1-9	1,856
	Age/Sex: 10-14 Male	975
	Age/Sex: 10-14 Female	1,068
	Age/Sex: 20-24 Male	799
	Age/Sex: 50+ Male	6,771
	Age/Sex: 20-24 Female	2,539
	Age/Sex: 50+ Female	5,130
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Female, Positive	4,121
	TX_CURR_N_TA_Age_Sex_HIVSt atus 25-29, Male, Positive	1,874
	TX_CURR_N_TA_Age_Sex_HIVSt atus 30-34, Female, Positive	5,376
TX_CURR_N_TA_Age_Sex_HIVSt	2,836	



	atus 30-34, Male, Positive	
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Female, Positive	5,721
	TX_CURR_N_TA_Age_Sex_HIVSt atus 35-39, Male, Positive	2,834
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Female, Positive	3,851
	TX_CURR_N_TA_Age_Sex_HIVSt atus 40-49, Male, Positive	1,745
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	443
	By Age/Sex: 1-9	3
	By Age/Sex: 10-14 Male	3
	By Age/Sex: 20-24 Male	4
	By Age/Sex: 50+ Male	26
	By Age/Sex: 10-14 Female	3
	By Age/Sex: 15-19 Female	13
	By Age/Sex: 20-24 Female	48
	By Age/Sex: 50+ Female	39
	FSW	290
	MSM	9
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Female, Positive	56
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 25-29, Male, Positive	4
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Female, Positive	35
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 30-34, Male, Positive	17
TX_NEW_N_DSD_Age_Sex_HIVS tatus 35-39, Female, Positive	35	
TX_NEW_N_DSD_Age_Sex_HIVS	61	



	tatus 35-39, Male, Positive	
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Female, Positive	61
	TX_NEW_N_DSD_Age_Sex_HIVS tatus 40-49, Male, Positive	35
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,789
	By Age/Sex: <1	11
	By Age/Sex: 1-9	87
	By Age/Sex: 10-14 Male	52
	By Age/Sex: 15-19 Male	131
	By Age/Sex: 20-24 Male	304
	By Age/Sex: 50+ Male	409
	By Age/Sex: 10-14 Female	49
	By Age/Sex: 15-19 Female	540
	By Age/Sex: 20-24 Female	1,276
	By Age/Sex: 50+ Female	480
	Sum of Age/Sex disaggregates	3,241
	Pregnancy status	998
	Breastfeeding status	297
	FSW	1,164
	MSM	52
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Female, Positive	712
	TX_NEW_N_TA_Age_Sex_HIVSta tus 25-29, Male, Positive	429
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Female, Positive	1,118
	TX_NEW_N_TA_Age_Sex_HIVSta tus 30-34, Male, Positive	560
TX_NEW_N_TA_Age_Sex_HIVSta tus 35-39, Female, Positive	1,046	



	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	562
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	651
	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	372
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	0 %
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	43,717
	Denominator: Indication: Routine	43,717
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,227
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	12,030
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,228
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	29,232
	TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy
Number of adults and children who are still alive and on treatment at 12 months after initiating ART		7,220
Total number of adults and children		8,020



	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
	Numerator by Status: Breastfeeding	759
	Denominator by Status: Pregnant	1,144
	Denominator by Status: Breastfeeding	835
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	496
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,944
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	529
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,251
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	554



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,134
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	585
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,747



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
16663	FHI 360	NGO	U.S. Agency for International Development		
16664	FHI 360	NGO	U.S. Agency for International Development		
17520	Engender Health	Private Contractor	U.S. Agency for International Development	GHP-State	800,000
17521	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	600,000
17552	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	1,500,000
17553	Metabiota	Private Contractor	U.S. Department of Defense		
18407	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	2,244,612
18408	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,220,000
18419	TBD	TBD	Redacted	Redacted	Redacted
18579	FHI 360	NGO	U.S. Agency for	GHP-State,	5,415,632



			International Development	GHP-USAID	
70018	TBD	TBD	Redacted	Redacted	Redacted
70020	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	560,717
70021	[Placeholder]	TBD	U.S. Agency for International Development		
70022	[Placeholder]	TBD	U.S. Agency for International Development		
70023	[Placeholder]	TBD	U.S. Agency for International Development		
70024	[Placeholder]	TBD	U.S. Agency for International Development		
70025	[Placeholder]	TBD	U.S. Agency for International Development		
70501	[Placeholder]	TBD	U.S. Department of State/Office of the Global AIDS Coordinator		



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 16663	Mechanism Name: Integrated Health Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16663		
Mechanism Name: Integrated Health Project		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16664	Mechanism Name: PMTCT Acceleration Project
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 16664		
Mechanism Name: PMTCT Acceleration Project		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17520	Mechanism Name: BRAVI
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Engender Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 800,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 800,000	
Funding Source	Funding Amount
GHP-State	800,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	800,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	60,000



Budget Code Information

Mechanism ID: 17520 Mechanism Name: BRAVI Prime Partner Name: Engender Health		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	18,481
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	140,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	110,759
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	420,000
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	110,760
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
GEND_GBV_DSD	Number of people receiving post-GBV care	201
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	200



GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	183
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	56
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	43
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	19
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	21
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	4

Implementing Mechanism Details

Mechanism ID: 17521	Mechanism Name: MEASURE Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 600,000	



Funding Source	Funding Amount
GHP-State	600,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17521 Mechanism Name: MEASURE Evaluation Phase IV Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	200,000
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	400,000
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17552	Mechanism Name: Strengthening services for key populations/LINKAGES
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

Gender: GBV	16,058
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Key Populations: FSW	1,089,760
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	398,792
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Condom procurement	5,316
Human Resources for Health	322,855

Budget Code Information

Mechanism ID: 17552		
Mechanism Name: Strengthening services for key populations/LINKAGES		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	149,672
Strategic Area	Budget Code	Planned Amount
Care	HKID	0



Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	144,036
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	185,723
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	849,265
Strategic Area	Budget Code	Planned Amount



Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	171,304
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,797
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,181
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	788
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV	249



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	167
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14,412
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,878
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	84
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,784
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	658



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	3,803
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	412
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,724
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female,	35



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	161
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	357
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	84
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_DSD	By Key Population: FSW, Negative	12,866
HTC_TST_DSD	By Key Population: FSW, Positive	982
HTC_TST_DSD	By Key Population: MSM, Negative	5,243
HTC_TST_DSD	By Key Population: MSM, Positive	119
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	523
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female,	75



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	8
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	34
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	338
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	75
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	26



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	50
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	16
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	83
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	28
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	76
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	18
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	22
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	2
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Negative	475
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Female, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Negative	533
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 25-29, Male, Positive	43



	Male, Positive	
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Negative	3,456
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Female, Positive	192
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Negative	1,070
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 30-34, Male, Positive	11
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Negative	878
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Female, Positive	124
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 35-39, Male, Negative	480
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Negative	470
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Female, Positive	27
HTC_TST_DSD	HTS_TST_N_DSD_MbMod_Age_Sex_Result 40-49, Male, Negative	24
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	27
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	98
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34,	9



	Male, Negative	
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	30
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	2
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	1
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	20
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	128
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	33
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	111
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	3
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	15
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	45
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	9
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	37
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	1
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	9



	Male, Negative	
GEND_GBV_DSD	Number of people receiving post-GBV care	326
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	320
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	243
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	56
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	41
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	91
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	53
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	56
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	1
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,370
TX_NEW_TA	By Age/Sex: <1	3
TX_NEW_TA	By Age/Sex: 1-9	3
TX_NEW_TA	By Age/Sex: 10-14 Male	5
TX_NEW_TA	By Age/Sex: 15-19 Male	1



TX_NEW_TA	By Age/Sex: 20-24 Male	21
TX_NEW_TA	By Age/Sex: 10-14 Female	5
TX_NEW_TA	By Age/Sex: 15-19 Female	119
TX_NEW_TA	By Age/Sex: 20-24 Female	306
TX_NEW_TA	By Age/Sex: 50+ Female	44
TX_NEW_TA	Sum of Age/Sex disaggregates	501
TX_NEW_TA	Pregnancy status	24
TX_NEW_TA	Breastfeeding status	6
TX_NEW_TA	FSW	942
TX_NEW_TA	MSM	52
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	92
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	33
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	342
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	44
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	250
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	28
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	69
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	5
HTS_SELF_DSD	HTS_SELF_N_DSD	2,876
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	28
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	28
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	28



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	28
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	143
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	143
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	143
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	143
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	58



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	173
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	114
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	114
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	58
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	1,954
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	922
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	182
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	181
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	559
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	910
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	444
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	948

Implementing Mechanism Details

Mechanism ID: 17553	Mechanism Name: Metabiota Burundi
Funding Agency: DOD	Procurement Type: Grant

Approved



Prime Partner Name: Metabiota	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17553		
Mechanism Name: Metabiota Burundi		
Prime Partner Name: Metabiota		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18407	Mechanism Name: GHSC-PSM
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,244,612	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,244,612	
Funding Source	Funding Amount
GHP-State	2,244,612

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18407		
Mechanism Name: GHSC-PSM		
Prime Partner Name: Chemonics International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	78,497
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	12,460
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	732,945
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	265,682
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	715,195
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	439,833
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18408	Mechanism Name: Youth Power
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 1,220,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,220,000	
Funding Source	Funding Amount
GHP-State	1,220,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Economic Strengthening	289,181
Human Resources for Health	75,000
Education	125,766
Motor Vehicles: Purchased	36,565

Budget Code Information

Mechanism ID: 18408		
Mechanism Name: Youth Power		
Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0



Strategic Area	Budget Code	Planned Amount
Care	HKID	1,220,000
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2019
GEND_GBVDSD	Number of people receiving post-GBV care	7
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	7
GEND_GBVDSD	10-14, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBVDSD	15-19, Male, Sexual Violence (Post-Rape Care)	5
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,037
OVC_SERVDSD	Age/Sex: 10-14 Female	5,950
OVC_SERVDSD	Age/Sex: 15-17 Female	3,201
OVC_SERVDSD	By: Age/sex: 18-24 Female	843
OVC_SERVDSD	Sum of Age/Sex disaggregates	9,151
OVC_SERVDSD	Program Completion: Active	8,537



OVC_SERV_DSD	Program Completion: Graduation	1,500
OVC_HIVSTAT_DSD	Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner.	8,700
OVC_HIVSTAT_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,037

Implementing Mechanism Details

Mechanism ID: 18419	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18579	Mechanism Name: Reaching an AIDS Free Generation (RAFG)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,415,632	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,415,632	
Funding Source	Funding Amount
GHP-State	3,415,632
GHP-USAID	2,000,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	101,367
-------------	---------



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	1,536,388

Budget Code Information

Mechanism ID: 18579 Mechanism Name: Reaching an AIDS Free Generation (RAFG) Prime Partner Name: FHI 360		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	63,151
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	189,453
Strategic Area	Budget Code	Planned Amount
Care	PDCS	126,302
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	1,099,598
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	OHSS	482,703
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	836,964
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	121,818
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	553,963
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	1,554,698
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	386,982



Implementing Mechanism Indicator Information

Indicator Number	Label	2019
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,422
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	177,642
PMTCT_ART_DSD	New on ART	1,077
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,345
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	177,642
PMTCT_STAT_DSD	Number of new ANC and L&D clients	186,987
PMTCT_STAT_DSD	By Age (Denominator): <15-19	23,047
PMTCT_STAT_DSD	By Age (Denominator): 20-24	56,468
PMTCT_STAT_DSD	By Number of known positives: 15-19	32
PMTCT_STAT_DSD	By Number of known positives: 20-24	252
PMTCT_STAT_DSD	By Number of known positives: 50+	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	139
PMTCT_STAT_DSD	By Number of new positives: 20-24	399
PMTCT_STAT_DSD	By Number of new negative: 15-19	20,882
PMTCT_STAT_DSD	By Number of new negative: 20-24	52,720
PMTCT_STAT_DSD	By Age (Numerator): 15-19	21,024
PMTCT_STAT_DSD	By Age (Numerator): 20-24	53,247
PMTCT_STAT_DSD	By Age (Numerator): 50+	3
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 25-29, Female	23,719
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 30-34, Female	30,286
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 35-39, Female	32,530
PMTCT_STAT_DSD	PMTCT_STAT_D_DSD_Age_Sex 40-49, Female	20,937



PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive	248
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative	22,395
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive	148
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive	302
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative	27,857
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive	196
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive	334
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative	31,524
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive	209
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive	222
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative	19,623
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive	131
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 25-29, Female	22,760
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 30-34, Female	28,327
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 35-39, Female	32,324
PMTCT_STAT_DSD	PMTCT_STAT_N_DSD_Age_Sex 40-49, Female	19,950
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	424,016
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	224
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male,	224



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	398
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	201
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	884
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	483
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	472
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	487
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	76
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	57
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	599
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	674
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	19



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	522
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,393
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	128
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	117
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,014
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	53
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,	8



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	109
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	157
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	263
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	287
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	239
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	3,073



HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	1,887
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	2,644
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	195
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	1,901
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	382
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	690
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	137
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	238
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,265
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	20,429
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	53,675
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	367
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,745
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	15



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2,001
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	19,728
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	362
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	8,700
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	113
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	30,750
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	841
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	19,306
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	207
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,876
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	259
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	3,777
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	243
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	1,023
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	8,168
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	80
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative	1,173



HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive	107
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative	1,160
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive	142
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative	1,530
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive	137
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative	1,360
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive	177
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative	1,651
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive	143
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative	1,649
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive	188
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative	1,065
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive	91
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative	1,034
HTC_TST_DSD	HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive	125
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative	440
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive	33



HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative	331
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative	564
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive	39
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative	391
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive	25
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative	639
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive	43
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative	472
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive	26
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative	441
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive	31
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative	316
HTC_TST_DSD	HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative	221
HTC_TST_DSD	HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Positive	6
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative	609



HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative	749
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative	817
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative	106
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative	534
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive	16
HTC_TST_DSD	HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative	77
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative	21,622
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive	165
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative	28,058
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive	220
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative	29,808
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive	233



HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative	21,430
HTC_TST_DSD	HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive	151
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive	20
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative	110
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive	18
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative	144
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative	147
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive	19
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative	146
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative	153
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive	22
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative	102
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive	21
HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative	108



HTC_TST_DSD	HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive	23
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative	11,146
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive	471
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative	10,113
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive	246
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative	16,467
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive	685
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative	13,580
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive	308
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative	15,556
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive	677
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative	13,834
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive	357
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative	10,060
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive	431
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative	9,874
HTC_TST_DSD	HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive	240



TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,375
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,375
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	51
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	69
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	872
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,383
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	61
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,383
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	58
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	873
GEND_GBV_DSD	Number of people receiving post-GBV care	614
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	607
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	444



GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	99
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	73
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	156
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	103
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	6
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	102
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 25-29, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 30-34, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 35-39, Female, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	GEND_GBV_N_DSD_Age_Sex_ViolenceType_v3 40-49, Female, Sexual Violence (Post-Rape Care)	1
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	176
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	88
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The	5



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	80
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,428
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,945
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	483
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,428
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	49,230
TX_CURR_TA	Age/Sex: 15-19 Male	742
TX_CURR_TA	Age/Sex: 15-19 Female	927
TX_CURR_TA	Sum of Age/Sex disaggregations	1,669
TX_CURR_TA	Age/Sex: <1	65
TX_CURR_TA	Age/Sex: 1-9	1,856
TX_CURR_TA	Age/Sex: 10-14 Male	975
TX_CURR_TA	Age/Sex: 10-14 Female	1,068
TX_CURR_TA	Age/Sex: 20-24 Male	799
TX_CURR_TA	Age/Sex: 50+ Male	6,771
TX_CURR_TA	Age/Sex: 20-24 Female	2,539
TX_CURR_TA	Age/Sex: 50+ Female	5,130
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	4,121
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	1,874
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	5,376



TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	2,836
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	5,721
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	2,834
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	3,851
TX_CURR_TA	TX_CURR_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	1,745
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,419
TX_NEW_TA	By Age/Sex: <1	8
TX_NEW_TA	By Age/Sex: 1-9	84
TX_NEW_TA	By Age/Sex: 10-14 Male	47
TX_NEW_TA	By Age/Sex: 15-19 Male	130
TX_NEW_TA	By Age/Sex: 20-24 Male	283
TX_NEW_TA	By Age/Sex: 50+ Male	409
TX_NEW_TA	By Age/Sex: 10-14 Female	44
TX_NEW_TA	By Age/Sex: 15-19 Female	421
TX_NEW_TA	By Age/Sex: 20-24 Female	970
TX_NEW_TA	By Age/Sex: 50+ Female	436
TX_NEW_TA	Sum of Age/Sex disaggregates	2,740
TX_NEW_TA	Pregnancy status	974
TX_NEW_TA	Breastfeeding status	291
TX_NEW_TA	FSW	222
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Female, Positive	620
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive	396
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Female, Positive	776
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive	516



	Positive	
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Female, Positive	796
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive	534
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Female, Positive	582
TX_NEW_TA	TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive	367
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	41,845
TX_PVLS_DSD	Denominator: Indication: Routine	41,845
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,174
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	11,514
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,175
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	27,982
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,762
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,511
TX_RET_DSD	Numerator by Status: Breastfeeding	759
TX_RET_DSD	Denominator by Status: Pregnant	635
TX_RET_DSD	Denominator by Status: Breastfeeding	835
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	491
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	1,823

	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	523
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,925
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	548
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,000
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	578
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,385
HTS_SELF_DSD	HTS_SELF_N_DSD	7,748
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted	80
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Unassisted	80
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted	80



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Unassisted	80
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted	388
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted	388
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted	388
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted	388
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted	461
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted	461
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted	461
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted	461
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted	461
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted	461
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted	157



HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted	461
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted	461
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted	309
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted	309
HTS_SELF_DSD	HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted	157
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted	5,242
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTest Unassisted	2,506
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Other	495
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self	497
HTS_SELF_DSD	HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner	1,514
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Directly-Assisted	2,580
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest FSW, Unassisted	1,216
HTS_SELF_DSD	HTS_SELF_N_DSD_KeyPop_HIVSelfTest MSM, Directly-Assisted	2,580
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,184

TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,922
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	147
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	113
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	3,028
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	1,634
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	125
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	96
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	2,570
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,393
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	3,445
TB_PREV_TA	TB_PREV_D_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,477
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive	2,929
TB_PREV_TA	TB_PREV_N_TA_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive	1,255
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	44,307
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	1,329
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	1,015
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	27,261
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	14,702
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	43,695
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	4,416



TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	13,197
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	26,082
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive	30,499
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive	4,351
TX_TB_TA	TX_TB_D_TA_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive	8,845

Implementing Mechanism Details

Mechanism ID: 70018	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 70020	Mechanism Name: GHSC - RTK
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70020		
Mechanism Name: GHSC - RTK		
Prime Partner Name: Chemonics International		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount



Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	560,717
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70021	Mechanism Name: [Placeholder - 70021 Burundi USAID]
Funding Agency: USAID	Procurement Type: Contract



Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70021		
Mechanism Name: [Placeholder - 70021 Burundi USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount



Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70022	Mechanism Name: [Placeholder - 70022 Burundi USAID]
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 70022		
Mechanism Name: [Placeholder - 70022 Burundi USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70023	Mechanism Name: [Placeholder - 70023 Burundi USAID]
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	70023	
Mechanism Name:	[Placeholder - 70023 Burundi USAID]	
Prime Partner Name:	[Placeholder]	
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount



Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0



Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70024	Mechanism Name: [Placeholder - 70024 Burundi USAID]
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 70024		
Mechanism Name: [Placeholder - 70024 Burundi USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount



Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70025	Mechanism Name: [Placeholder - 70025 Burundi USAID]
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: [Placeholder]	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 70025		
Mechanism Name: [Placeholder - 70025 Burundi USAID]		
Prime Partner Name: [Placeholder]		
Strategic Area	Budget Code	Planned Amount
Care	HBHC	0
Strategic Area	Budget Code	Planned Amount
Care	HKID	0
Strategic Area	Budget Code	Planned Amount
Care	HVTB	0
Strategic Area	Budget Code	Planned Amount
Care	PDCS	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	HLAB	0



Strategic Area	Budget Code	Planned Amount
Governance and Systems	HVSI	0
Strategic Area	Budget Code	Planned Amount
Governance and Systems	OHSS	0
Strategic Area	Budget Code	Planned Amount
Prevention	CIRC	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMBL	0
Strategic Area	Budget Code	Planned Amount
Prevention	HMIN	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVAB	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVCT	0
Strategic Area	Budget Code	Planned Amount
Prevention	HVOP	0
Strategic Area	Budget Code	Planned Amount
Prevention	IDUP	0
Strategic Area	Budget Code	Planned Amount
Prevention	MTCT	0
Strategic Area	Budget Code	Planned Amount
Treatment	HTXD	0
Strategic Area	Budget Code	Planned Amount

Approved



Treatment	HTXS	0
Strategic Area	Budget Code	Planned Amount
Treatment	PDTX	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 70501	TBD: Yes
REDACTED	



**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Staff Program Travel		103,600		103,600	0	103,600
USG Staff Salaries and Benefits - Internationally Recruited		170,994		170,994	160,237	331,231
USG Staff Salaries and Benefits - Locally Recruited		593,279		593,279	0	593,279
Total	0	867,873	0	867,873	160,237	1,028,110

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT		5,000		5,000	0	5,000

Approved



Services						
ICASS		20,000		20,000	0	20,000
Staff Program Travel		25,000		25,000	0	25,000
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		70,000		70,000	0	70,000
Total	0	120,000	0	120,000	0	120,000